Insulin injection - Rezolute
Alternative Names: AB 101; InsuLAR; Long-acting insulinLatest Information Update: 28 Feb 2023
At a glance
- Originator PR Pharmaceuticals
- Developer Rezolute
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (SC, Injection)
- 27 Sep 2021 Adverse events and pharmacokinetics data from a phase I trial in Diabetes mellitus presented at the 57th Annual Meeting of the European Association for the Study of Diabetes
- 28 Aug 2020 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Injection)